Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight
November 18, 2021 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting
November 04, 2021 08:00 ET
|
Advaxis, Inc.
Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders Advaxis urges stockholders to vote “FOR” all of the proposals at...
Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
November 03, 2021 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
September 10, 2021 08:30 ET
|
Advaxis, Inc.
Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies Initiated Phase 1 clinical trial of...
Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.
August 11, 2021 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and...
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
July 15, 2021 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
July 14, 2021 16:01 ET
|
Advaxis, Inc.
PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
July 06, 2021 06:00 ET
|
Advaxis, Inc.
– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and...
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
June 14, 2021 16:05 ET
|
Advaxis, Inc.
ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA® ...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 19, 2021 17:01 ET
|
Advaxis, Inc.
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of...